Precompetitive data sharing as a catalyst to address unmet needs in Parkinson's disease

Diane Stephenson*, Michele T. Hu, Klaus Romero, Kieran Breen, David Burn, Yoav Ben-Shlomo, Atul Bhattaram, Maria Isaac, Charles Venuto, Ken Kubota, Max A. Little, Stephen Friend, Simon Lovestone, Huw R. Morris, Donald Grosset, Margaret Sutherland, John Gallacher, Caroline Williams-Gray, Lisa J. Bain, Enrique AvilésKen Marek, Arthur W. Toga, Yafit Stark, Mark Forrest Gordon, Steve Ford

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Parkinson's disease is a complex heterogeneous disorder with urgent need for disease-modifying therapies. Progress in successful therapeutic approaches for PD will require an unprecedented level of collaboration. At a workshop hosted by Parkinson's UK and co-organized by Critical Path Institute's (C-Path) Coalition Against Major Diseases (CAMD) Consortiums, investigators from industry, academia, government and regulatory agencies agreed on the need for sharing of data to enable future success. Government agencies included EMA, FDA, NINDS/NIH and IMI (Innovative Medicines Initiative). Emerging discoveries in new biomarkers and genetic endophenotypes are contributing to our understanding of the underlying pathophysiology of PD. In parallel there is growing recognition that early intervention will be key for successful treatments aimed at disease modification. At present, there is a lack of a comprehensive understanding of disease progression and the many factors that contribute to disease progression heterogeneity. Novel therapeutic targets and trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination are required. The integration of robust clinical data sets is viewed as a powerful approach to hasten medical discovery and therapies, as is being realized across diverse disease conditions employing big data analytics for healthcare. The application of lessons learned from parallel efforts is critical to identify barriers and enable a viable path forward. A roadmap is presented for a regulatory, academic, industry and advocacy driven integrated initiative that aims to facilitate and streamline new drug trials and registrations in Parkinson's disease.

Original languageEnglish
Pages (from-to)581-594
Number of pages14
JournalJournal of Parkinson's Disease
Volume5
Issue number3
DOIs
Publication statusPublished - 14 Sep 2015

Fingerprint

Information Dissemination
Parkinson Disease
Government Agencies
Disease Progression
Industry
Biomarkers
National Institute of Neurological Disorders and Stroke
Endophenotypes
Critical Pathways
Therapeutics
Pharmaceutical Preparations
Research Personnel
Delivery of Health Care
Education

Bibliographical note

© 2015 – IOS Press and the authors. All rights reserved. This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License.

Keywords

  • collaboration
  • data integration
  • data standards
  • privacy
  • quantitative disease progression
  • regulatory science

Cite this

Stephenson, D., Hu, M. T., Romero, K., Breen, K., Burn, D., Ben-Shlomo, Y., ... Ford, S. (2015). Precompetitive data sharing as a catalyst to address unmet needs in Parkinson's disease. Journal of Parkinson's Disease, 5(3), 581-594. https://doi.org/10.3233/JPD-150570
Stephenson, Diane ; Hu, Michele T. ; Romero, Klaus ; Breen, Kieran ; Burn, David ; Ben-Shlomo, Yoav ; Bhattaram, Atul ; Isaac, Maria ; Venuto, Charles ; Kubota, Ken ; Little, Max A. ; Friend, Stephen ; Lovestone, Simon ; Morris, Huw R. ; Grosset, Donald ; Sutherland, Margaret ; Gallacher, John ; Williams-Gray, Caroline ; Bain, Lisa J. ; Avilés, Enrique ; Marek, Ken ; Toga, Arthur W. ; Stark, Yafit ; Gordon, Mark Forrest ; Ford, Steve. / Precompetitive data sharing as a catalyst to address unmet needs in Parkinson's disease. In: Journal of Parkinson's Disease. 2015 ; Vol. 5, No. 3. pp. 581-594.
@article{69553dd8586a41f0a4258512b9e772ae,
title = "Precompetitive data sharing as a catalyst to address unmet needs in Parkinson's disease",
abstract = "Parkinson's disease is a complex heterogeneous disorder with urgent need for disease-modifying therapies. Progress in successful therapeutic approaches for PD will require an unprecedented level of collaboration. At a workshop hosted by Parkinson's UK and co-organized by Critical Path Institute's (C-Path) Coalition Against Major Diseases (CAMD) Consortiums, investigators from industry, academia, government and regulatory agencies agreed on the need for sharing of data to enable future success. Government agencies included EMA, FDA, NINDS/NIH and IMI (Innovative Medicines Initiative). Emerging discoveries in new biomarkers and genetic endophenotypes are contributing to our understanding of the underlying pathophysiology of PD. In parallel there is growing recognition that early intervention will be key for successful treatments aimed at disease modification. At present, there is a lack of a comprehensive understanding of disease progression and the many factors that contribute to disease progression heterogeneity. Novel therapeutic targets and trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination are required. The integration of robust clinical data sets is viewed as a powerful approach to hasten medical discovery and therapies, as is being realized across diverse disease conditions employing big data analytics for healthcare. The application of lessons learned from parallel efforts is critical to identify barriers and enable a viable path forward. A roadmap is presented for a regulatory, academic, industry and advocacy driven integrated initiative that aims to facilitate and streamline new drug trials and registrations in Parkinson's disease.",
keywords = "collaboration, data integration, data standards, privacy, quantitative disease progression, regulatory science",
author = "Diane Stephenson and Hu, {Michele T.} and Klaus Romero and Kieran Breen and David Burn and Yoav Ben-Shlomo and Atul Bhattaram and Maria Isaac and Charles Venuto and Ken Kubota and Little, {Max A.} and Stephen Friend and Simon Lovestone and Morris, {Huw R.} and Donald Grosset and Margaret Sutherland and John Gallacher and Caroline Williams-Gray and Bain, {Lisa J.} and Enrique Avil{\'e}s and Ken Marek and Toga, {Arthur W.} and Yafit Stark and Gordon, {Mark Forrest} and Steve Ford",
note = "{\circledC} 2015 – IOS Press and the authors. All rights reserved. This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License.",
year = "2015",
month = "9",
day = "14",
doi = "10.3233/JPD-150570",
language = "English",
volume = "5",
pages = "581--594",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "IOS",
number = "3",

}

Stephenson, D, Hu, MT, Romero, K, Breen, K, Burn, D, Ben-Shlomo, Y, Bhattaram, A, Isaac, M, Venuto, C, Kubota, K, Little, MA, Friend, S, Lovestone, S, Morris, HR, Grosset, D, Sutherland, M, Gallacher, J, Williams-Gray, C, Bain, LJ, Avilés, E, Marek, K, Toga, AW, Stark, Y, Gordon, MF & Ford, S 2015, 'Precompetitive data sharing as a catalyst to address unmet needs in Parkinson's disease', Journal of Parkinson's Disease, vol. 5, no. 3, pp. 581-594. https://doi.org/10.3233/JPD-150570

Precompetitive data sharing as a catalyst to address unmet needs in Parkinson's disease. / Stephenson, Diane; Hu, Michele T.; Romero, Klaus; Breen, Kieran; Burn, David; Ben-Shlomo, Yoav; Bhattaram, Atul; Isaac, Maria; Venuto, Charles; Kubota, Ken; Little, Max A.; Friend, Stephen; Lovestone, Simon; Morris, Huw R.; Grosset, Donald; Sutherland, Margaret; Gallacher, John; Williams-Gray, Caroline; Bain, Lisa J.; Avilés, Enrique; Marek, Ken; Toga, Arthur W.; Stark, Yafit; Gordon, Mark Forrest; Ford, Steve.

In: Journal of Parkinson's Disease, Vol. 5, No. 3, 14.09.2015, p. 581-594.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Precompetitive data sharing as a catalyst to address unmet needs in Parkinson's disease

AU - Stephenson, Diane

AU - Hu, Michele T.

AU - Romero, Klaus

AU - Breen, Kieran

AU - Burn, David

AU - Ben-Shlomo, Yoav

AU - Bhattaram, Atul

AU - Isaac, Maria

AU - Venuto, Charles

AU - Kubota, Ken

AU - Little, Max A.

AU - Friend, Stephen

AU - Lovestone, Simon

AU - Morris, Huw R.

AU - Grosset, Donald

AU - Sutherland, Margaret

AU - Gallacher, John

AU - Williams-Gray, Caroline

AU - Bain, Lisa J.

AU - Avilés, Enrique

AU - Marek, Ken

AU - Toga, Arthur W.

AU - Stark, Yafit

AU - Gordon, Mark Forrest

AU - Ford, Steve

N1 - © 2015 – IOS Press and the authors. All rights reserved. This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License.

PY - 2015/9/14

Y1 - 2015/9/14

N2 - Parkinson's disease is a complex heterogeneous disorder with urgent need for disease-modifying therapies. Progress in successful therapeutic approaches for PD will require an unprecedented level of collaboration. At a workshop hosted by Parkinson's UK and co-organized by Critical Path Institute's (C-Path) Coalition Against Major Diseases (CAMD) Consortiums, investigators from industry, academia, government and regulatory agencies agreed on the need for sharing of data to enable future success. Government agencies included EMA, FDA, NINDS/NIH and IMI (Innovative Medicines Initiative). Emerging discoveries in new biomarkers and genetic endophenotypes are contributing to our understanding of the underlying pathophysiology of PD. In parallel there is growing recognition that early intervention will be key for successful treatments aimed at disease modification. At present, there is a lack of a comprehensive understanding of disease progression and the many factors that contribute to disease progression heterogeneity. Novel therapeutic targets and trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination are required. The integration of robust clinical data sets is viewed as a powerful approach to hasten medical discovery and therapies, as is being realized across diverse disease conditions employing big data analytics for healthcare. The application of lessons learned from parallel efforts is critical to identify barriers and enable a viable path forward. A roadmap is presented for a regulatory, academic, industry and advocacy driven integrated initiative that aims to facilitate and streamline new drug trials and registrations in Parkinson's disease.

AB - Parkinson's disease is a complex heterogeneous disorder with urgent need for disease-modifying therapies. Progress in successful therapeutic approaches for PD will require an unprecedented level of collaboration. At a workshop hosted by Parkinson's UK and co-organized by Critical Path Institute's (C-Path) Coalition Against Major Diseases (CAMD) Consortiums, investigators from industry, academia, government and regulatory agencies agreed on the need for sharing of data to enable future success. Government agencies included EMA, FDA, NINDS/NIH and IMI (Innovative Medicines Initiative). Emerging discoveries in new biomarkers and genetic endophenotypes are contributing to our understanding of the underlying pathophysiology of PD. In parallel there is growing recognition that early intervention will be key for successful treatments aimed at disease modification. At present, there is a lack of a comprehensive understanding of disease progression and the many factors that contribute to disease progression heterogeneity. Novel therapeutic targets and trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination are required. The integration of robust clinical data sets is viewed as a powerful approach to hasten medical discovery and therapies, as is being realized across diverse disease conditions employing big data analytics for healthcare. The application of lessons learned from parallel efforts is critical to identify barriers and enable a viable path forward. A roadmap is presented for a regulatory, academic, industry and advocacy driven integrated initiative that aims to facilitate and streamline new drug trials and registrations in Parkinson's disease.

KW - collaboration

KW - data integration

KW - data standards

KW - privacy

KW - quantitative disease progression

KW - regulatory science

UR - http://www.scopus.com/inward/record.url?scp=84941793151&partnerID=8YFLogxK

U2 - 10.3233/JPD-150570

DO - 10.3233/JPD-150570

M3 - Article

AN - SCOPUS:84941793151

VL - 5

SP - 581

EP - 594

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 3

ER -